Diagnosis of Human Malignances Associated with Activating Mutations of Platelet Derived Growth Factor Receptor Alpha (PDGFRA)
OHSU # 0614
Tyrosine kinases are expressed in many human cancers and are attractive targets for the development of anticancer therapies. Clinical response to these therapies is often correlated with the mutational status of the target. The identification of a particular mutation in a patient’s tumor therefore can be used to identify which patients are most likely to respond to treatment.
OHSU investigators have discovered novel mutations of a type III receptor tyrosine kinase, platelet derived growth factor receptor alpha (PDGFR alpha, PDGFRα, PDGFRA) that result in activation of this tyrosine kinase. This technology provides methods and kits of identifying novel PDGFR alpha proteins and nucleic acids encoding these variants in human samples.
PDGFR alpha mutations identified in gastrointestinal stromal tumors (GISTs) include:
Heinrich MC, Corless CL, Duensing A, McGreevy L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 2003 299(5607):708-710
U.S. Patent Nos. 7,595,154 and 7,875,710
This technology is available for licensing.
- Jonathon Fletcher
- George Demitri
- Michael Heinrich, SM.Knight Hem/Onc Admin
- Christopher Corless, SM.Knight Laboratory Mgmt
For more information, contact:
Technology Development Manager